Immuno-oncology drugs mainly use drugs to mediate a functional immune system to inhibit cell growth to achieve tumor suppression. Therefore, in preclinical animal efficacy experiments, it is necessary to use mice with normal immune systems to inoculate homologous tumor cells to establish the syngeneic models.
TruwayBio has established following syngeneic models:
Breast cancer model: 4T-1
Colon cancer model: CT-26; MC-38
Kidney tumor model: Renca
Liver cancer model: H22, Hepa 1-6
Melanoma model: B16F10
Pancreatic cancer model: Panc02